Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 9/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.43 |
| ▸ | NMT2 | O60551 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cromolyn SCHEMBL3865 | 1.00 | GPR35 (1.00) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL29352570 | 1.00 | GPR35 (1.00) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL8662365 | 0.99 | GPR35 (0.97) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL4108171 | 0.99 | GPR35 (0.97) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL318268 | 0.99 | GPR35 (0.97) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL8199 | 0.99 | GPR35 (0.97) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL11253121 | 0.96 | GPR35 (0.93) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL11832140 | 0.94 | GPR35 (0.88) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL11175797 | 0.94 | GPR35 (0.88) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL2717434 | 0.94 | GPR35 (0.88) | GPR35LMNATDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 975 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | claimed |
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4596049-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| WO-2025137230-A1 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF INADEQUATELY CONTROLLED MODERATE TO SEVERE ASTHMA | ARETEIA THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-12337065-B2 | Compositions for treating viral infections and methods for same | ACCESS TO ADVANCED HEALTH INSTITUTE (US) | 2025-06-24 | — | — | US | claimed |
| WO-2025128784-A1 | METHODS AND COMPOSITIONS FOR TREATING LIVER DISEASE | SEN-JAM PHARMACEUTICAL INC. (US) | 2025-06-19 | — | — | WO | claimed |
| EP-4302829-B1 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC (US) | 2025-05-21 | — | — | EP | claimed |
| US-12297294-B2 | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | BCN PEPTIDES, S.A. (ES) | 2025-05-13 | — | — | US | claimed |
| WO-2023069255-A1 | METHODS AND COMPOSITIONS COMPRISING PEPTIDOMIMITICS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-27 | — | — | WO | claimed |
| WO-2023069549-A1 | METHODS AND COMPOSITIONS COMPRISING PEPTIDOMIMITICS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-27 | — | — | WO | claimed |
| US-11612633-B2 | Methods and compositions for preventing or treating ophthalmic conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-03-28 | — | — | US | claimed |
| US-11602603-B2 | Nasal delivery devices | Optinose, Inc. (US) | 2023-03-14 | — | — | US | claimed |
| US-20220387408-A1 | USE OF MAST CELL STABILIZER FOR THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | INST NAT SANTE RECH MED (FR) | 2022-12-08 | — | — | US | claimed |
| EP-4058010-A1 | USE OF MAST CELL STABILIZER FOR THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-09-21 | — | — | EP | claimed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | claimed |
| US-20220265670-A1 | COMPOSITION AND USE THEREOF FOR THE TREATMENT OF CUTANEOUS MASTOCYTOSIS | AC BIOSCIENCE SA (CH) | 2022-08-25 | — | — | US | claimed |
| EP-3972574-A1 | COMPOSITION AND USE THEREOF FOR THE TREATMENT OF CUTANEOUS MASTOCYTOSIS | AC BioScience SA (CH) | 2022-03-30 | — | — | EP | claimed |
| US-20220031980-A1 | NASAL DELIVERY DEVICES | OAKTREE FUND ADMINISTRATION, LLC | 2022-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | NR2E3, ALDH1A2, PDE6D | GPR35 3784/4885LMNA 27/4885TDP1 434/4885 |
| US-20220265670-A1 | COMPOSITION AND USE THEREOF FOR THE TREATMENT OF CUTANEOUS MASTOCYTOSIS | CPA3, KIT, CMA1 | GPR35 454/4885LMNA 2081/4885TDP1 3196/4885 |
| US-12297294-B2 | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | GHSR, GIPR, GHRHR | GPR35 103/4885LMNA 4606/4885TDP1 4590/4885 |
| US-11612633-B2 | Methods and compositions for preventing or treating ophthalmic conditions | CRYAA, CRYAB, IAPP | GPR35 1288/4885LMNA 1439/4885TDP1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.